^
    1d
    Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (clinicaltrials.gov)
    P1/2, N=1410, Active, not recruiting, Klus Pharma Inc. | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + ER positive
    |
    Jiataile (sacituzumab tirumotecan)
    1d
    DESTINY PanTumor03: A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors (clinicaltrials.gov)
    P2, N=127, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Avastin (bevacizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    1d
    Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response. (PubMed, Oncogene)
    We also propose dual HER2/EGFR targeting and non-CB2R-selective cannabinoid therapies as potential strategies to overcome CB2R-mediated trastuzumab resistance. Together, these findings position the endocannabinoid system as a pivotal and actionable node to elucidate, anticipate, and counteract resistance to HER2-targeted therapies.
    Journal
    |
    IFNG (Interferon, gamma)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab)
    2d
    LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=400, Recruiting, LaNova Medicines Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    HER-2 negative • HER-2 expression
    |
    paclitaxel • Loqtorzi (toripalimab-tpzi) • cafelkibart (LM-108)
    2d
    Population Pharmacokinetics of Trastuzumab Rezetecan in Patients With HER2-Expressing or Mutated Advanced Solid Tumors. (PubMed, CPT Pharmacometrics Syst Pharmacol)
    Based on the covariate analysis, no dose adjustments are warranted for the studied patient population. This model can further support dose selection in future clinical trials through exposure-response analyses.
    PK/PD data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • HER-2 expression
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811)
    3d
    OPTIMA-YOUNG: Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests (clinicaltrials.gov)
    P3, N=3380, Not yet recruiting, UNICANCER
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative • HER-2 expression
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    3d
    DESTINY-Endometrial02: Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (clinicaltrials.gov)
    P3, N=710, Recruiting, Daiichi Sankyo
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    carboplatin • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki)
    3d
    Discordance between IHC/FISH and RNA expression-based assessment of ER/HER2 status, and its prognostic impact assessed by propensity score matching. (PubMed, BMC Cancer)
    ER and HER2 RNA expression levels should be considered for confirmation in patients with PR-negative/HER2-positive status, as discordance between IHC and RNA-based assessment is significantly associated with worse recurrence-free survival outcomes.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • HER-2 expression
    3d
    Differential response of HER2 - and HER2 + breast cancer cells to quinazoline and triazole derivatives: advancing receptor subtype-specific phytochemical targeting. (PubMed, Mol Divers)
    The HER2 - cells showed a greater reduction in ER expression with the quinazoline derivative (F0922-0471) than with the triazole derivative, which significantly reduced HER2 expression in HER2 + cells, underscoring their receptor-specific effects. This study concludes that Quinazoline (F0922-0471) and Triazole derivatives (F2865-0609) show potential as receptor-specific, multi-targeted anticancer agents for distinct breast cancer subtypes, warranting further preclinical and clinical evaluations.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression
    4d
    IKS014-01: IKS014 in Advanced Solid Tumors That Express HER2 (clinicaltrials.gov)
    P1, N=165, Recruiting, Iksuda Therapeutics Ltd. | Trial completion date: Sep 2027 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 positive • HR positive • HER-2 amplification • HER-2 expression • HER-2 amplification + HR-positive
    |
    caxmotabart entudotin (IKS014)
    4d
    Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy (clinicaltrials.gov)
    P1, N=30, Recruiting, Vanderbilt-Ingram Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 amplification • HER-2 expression
    5d
    The VEGF/VEGFR axis in triple-negative breast cancer: a comprehensive review of therapeutic strategies. (PubMed, Gene)
    In addition, we highlight the importance of molecular stratification and biomarker-driven approaches to identify patients most likely to benefit from anti-angiogenic therapy. Overall, while VEGFR-targeted therapy alone has shown limited success, rational combination strategies and improved patient selection may significantly enhance its clinical utility in TNBC.
    Review • Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 expression